{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T00:07:53Z","timestamp":1771286873579,"version":"3.50.1"},"reference-count":50,"publisher":"Georg Thieme Verlag KG","issue":"01","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Aktuelle Urol"],"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title>\n                  <jats:p>Nierenzellkarzinome geh\u00f6ren zu den h\u00e4ufigsten malignen Tumoren des Urogenitaltrakts.\n      Aktuell umfasst die WHO-Klassifikation der Nierentumoren \u00fcber 20 Subtypen, zum Teil mit einem\n      spezifischen molekular-genetischen Hintergrund. Die neue WHO-Klassifikation unterteilt die\n      Tumore in morphologisch und molekular definierte Tumoren. Neben den klassischen Subtypen wie\n      klarzelligen, papill\u00e4ren und chromophoben Nierenzellkarzinomen, wurden neue Entit\u00e4ten\n      definiert, wie zum Beispiel das eosinophile solid und zystische Nierenzellkarzinom. In die\n      Kategorie der molekular definierten Nierentumoren geh\u00f6ren die Nierenzellkarzinome mit\n      TFE3-Rearrangement, die TFEB-alterierten Nierenzellkarzinome, ELOC-mutierte\n      Nierenzellkarzinome, Fumarat-Hydratase-defiziente Nierenzellkarzinome,\n      Succinatdehydrogenase-defiziente Nierenzellkarzinome, Nierenzellkarzinome mit\n      ALK-Rearrangement und SMARCB1-defiziente medull\u00e4re Nierenzellkarzinome. Dank neuen\n      Erkenntnissen bez\u00fcglich der langen \u00dcberlebenszeit und fehlender Fernmetastasierung werden\n      mehrere Subtypen nicht mehr als Karzinom, sondern als Nierentumor, wie zum Beispiel der\n      multilokul\u00e4r-zystische Nierentumor oder der klarzellig-papill\u00e4re Nierentumor, klassifiziert.\n      In der WHO-Klassifikation wurde die Wichtigkeit der genetisch bedingten Nierentumoren\n      unterstrichen, denen sich ein separates Kapitel widmet. Aktuell werden molekulare Analysen f\u00fcr\n      die Therapieentscheidung in fortgeschrittenen F\u00e4llen nach molekularen Tumorboardbesprechungen\n      eingesetzt. Deshalb gewinnt die Klassifikation der Subtypen und damit verbunden die\n      spezifischen molekularen Alterationen und Signalwege f\u00fcr die zielgerichtete Systemtherapie,\n      aber auch f\u00fcr die Identifizierung von Patienten mit einem heredit\u00e4ren Tumorsyndrom immer mehr\n      an Bedeutung.Die Aufgaben der Pathologen ist es, die neuen Tumorentit\u00e4ten und die\n      genetisch vererbten Tumorformen zu identifizieren, um die bestm\u00f6gliche klinische Betreuung der\n      Patienten zu gew\u00e4hrleisten.<\/jats:p>","DOI":"10.1055\/a-2714-2212","type":"journal-article","created":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T23:47:14Z","timestamp":1764892034000},"page":"66-77","source":"Crossref","is-referenced-by-count":0,"title":["Neue WHO-Klassifikation der Nierenzelltumore \u2013 Implikationen f\u00fcr eine individuelle Therapieentscheidung und die ad\u00e4quate Erkennung von erblichen Nierenzellkarzinomen"],"prefix":"10.1055","volume":"57","author":[{"given":"Marieta Ioana","family":"Toma","sequence":"additional","affiliation":[{"name":"University Bonn, Institute of Pathology, University Hospital Bonn, Bonn, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roman-Ulrich","family":"M\u00fcller","sequence":"additional","affiliation":[{"name":"Medical Clinic II, University Hospital Cologne, Cologne, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2083-7687","authenticated-orcid":false,"given":"Viktor","family":"Gr\u00fcnwald","sequence":"additional","affiliation":[{"name":"Urology and Medical Oncology, University Duisburg-Essen, Essen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arndt","family":"Hartmann","sequence":"additional","affiliation":[{"name":"Institute of Pathology, University Clinic Erlangen, Erlangen, Germany"},{"name":"University Erlangen-N\u00fcrnberg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0873-8128","authenticated-orcid":false,"given":"Kerstin","family":"Junker","sequence":"additional","affiliation":[{"name":"Dept of Urology and Pediatric Urology, Saarland University Hospital and Saarland University Faculty of Medicine, Homburg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2025,12,4]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"13862","DOI":"10.1038\/s41598-020-70840-2","article-title":"The burden of kidney cancer and its attributable risk factors in 195 countries and territories, 1990\u20132017","volume":"10","author":"S Safiri","year":"2020","journal-title":"Scientific reports"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1016\/j.annonc.2025.03.016","article-title":"Prospective randomized phase-II trial of ipilimumab\/nivolumab versus standard of care in non-clear cell renal cell cancer \u2013 results of the SUNNIFORECAST trial","volume":"36","author":"L Bergmann","year":"2025","journal-title":"Annals of oncology"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.eururo.2018.03.032","article-title":"Responses to Alectinib in ALK-rearranged Papillary Renal Cell Carcinoma","volume":"74","author":"SK Pal","year":"2018","journal-title":"European urology"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1016\/j.eururo.2015.10.049","article-title":"Everolimus Versus Sunitinib Prospective Evaluation in Metastatic Non-Clear Cell Renal Cell Carcinoma (ESPN): A Randomized Multicenter Phase 2 Trial","volume":"69","author":"NM Tannir","year":"2016","journal-title":"European urology"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1159\/000508450","article-title":"A Randomized Phase IIa Trial with Temsirolimus versus Sunitinib in Advanced Non-Clear Cell Renal Cell Carcinoma: An Intergroup Study of the CESAR Central European Society for Anticancer Drug Research-EWIV and the Interdisciplinary Working Group on Renal Cell Cancer (IAGN) of the German Cancer Society","volume":"43","author":"L Bergmann","year":"2020","journal-title":"Oncology research and treatment"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.eururo.2016.02.029","article-title":"The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs-Part A: Renal, Penile, and Testicular Tumours","volume":"70","author":"H Moch","year":"2016","journal-title":"European urology"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"1968","DOI":"10.1200\/JCO.2012.45.2003","article-title":"Molecular genetics of clear-cell renal cell carcinoma","volume":"32","author":"J Brugarolas","year":"2014","journal-title":"Journal of clinical oncology"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1158\/2159-8290.CD-18-1354","article-title":"The Metabolic Basis of Kidney Cancer","volume":"9","author":"WM Linehan","year":"2019","journal-title":"Cancer discovery"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.1097\/PAS.0b013e318299f0fb","article-title":"The International Society of Urological Pathology (ISUP) grading system for renal cell carcinoma and other prognostic parameters","volume":"37","author":"B Delahunt","year":"2013","journal-title":"The American journal of surgical pathology"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"2036","DOI":"10.1002\/ijc.35141","article-title":"Clinical features and response to immune combinations in patients with renal cell carcinoma and sarcomatoid de-differentiation (ARON-1 study)","volume":"155","author":"C Ciccarese","year":"2014","journal-title":"International journal of cancer"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1016\/j.annonc.2024.05.537","article-title":"Renal cell carcinoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"35","author":"T Powles","year":"2024","journal-title":"Annals of oncology"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-005445","article-title":"Long-term outcomes with nivolumab plus ipilimumab versus sunitinib in first-line treatment of patients with advanced sarcomatoid renal cell carcinoma","volume":"10","author":"BI Rini","year":"2022","journal-title":"Journal for immunotherapy of cancer"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1200\/JCO.24.00773","article-title":"Adjuvant Nivolumab for Localized Renal Cell Carcinoma at High Risk of Recurrence After Nephrectomy: Part B of the Randomized, Placebo-Controlled, Phase III CheckMate 914 Trial","volume":"43","author":"RJ Motzer","year":"2025","journal-title":"Journal of clinical oncology"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1056\/NEJMoa1505917","article-title":"Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma","volume":"374","author":"WM Linehan","year":"2016","journal-title":"The New England journal of medicine"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1093\/ndt\/gfaf032","article-title":"The impact of the new WHO classification of renal cell carcinoma on the diagnosis of hereditary leiomyomatosis and renal cell carcinoma","volume":"40","author":"J Degenhardt","year":"2025","journal-title":"Nephrology, dialysis, transplantation"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1007\/s00428-004-1187-x","article-title":"Chromophobe renal cell carcinoma with microcystic and adenomatous arrangement and pigmentation \u2013 a diagnostic pitfall. Morphological, immunohistochemical, ultrastructural and molecular genetic report of 20 cases","volume":"446","author":"O Hes","year":"2005","journal-title":"Virchows Archiv"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1016\/j.urolonc.2007.07.015","article-title":"Pathobiology and prognosis of chromophobe renal cell carcinoma","volume":"26","author":"T Klatte","year":"2008","journal-title":"Urologic oncology"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1007\/s00428-019-02710-w","article-title":"Multi-institutional re-evaluation of prognostic factors in chromophobe renal cell carcinoma: proposal of a novel two-tiered grading scheme","volume":"476","author":"R Ohashi","year":"2020","journal-title":"Virchows Archiv"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"1822","DOI":"10.1097\/PAS.0b013e3181831e68","article-title":"Chromophobe renal cell carcinoma: histomorphologic characteristics and evaluation of conventional pathologic prognostic parameters in 145 cases","volume":"32","author":"MB Amin","year":"2008","journal-title":"The American journal of surgical pathology"},{"key":"ref20","volume-title":"Urinary and male genital tumours","author":"WHO Classification of Tumours Editorial Board","year":"2022","edition":"5"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"e553","DOI":"10.1016\/j.clgc.2016.03.017","article-title":"Multilocular Cystic Renal Cell Neoplasm of Low Malignant Potential: A Series of 76 Cases","volume":"14","author":"T Li","year":"2016","journal-title":"Clinical genitourinary cancer"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1309\/AH6F-C77P-YR2V-6YAY","article-title":"Multilocular cystic renal cell carcinoma : a report of 45 cases of a kidney tumor of low malignant potential","volume":"125","author":"S Suzigan","year":"2006","journal-title":"American journal of clinical pathology"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.1097\/PAS.0b013e3181f2ee0b","article-title":"Clear cell tubulopapillary renal cell carcinoma: a study of 36 distinctive low-grade epithelial tumors of the kidney","volume":"34","author":"H Aydin","year":"2010","journal-title":"The American journal of surgical pathology"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1097\/01.pas.0000185382.80844.b1","article-title":"Spectrum of epithelial neoplasms in end-stage renal disease: an experience from 66 tumor-bearing kidneys with emphasis on histologic patterns distinct from those in sporadic adult renal neoplasia","volume":"30","author":"SK Tickoo","year":"2006","journal-title":"The American journal of surgical pathology"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1111\/his.13727","article-title":"New and emerging renal entities: a perspective post-WHO 2016 classification","volume":"74","author":"K Trpkov","year":"2019","journal-title":"Histopathology"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1097\/PAS.0000000000001422","article-title":"\"Renal Cell Carcinoma With Leiomyomatous Stroma\" Harbor Somatic Mutations of TSC1, TSC2, MTOR, and\/or ELOC (TCEB1): Clinicopathologic and Molecular Characterization of 18 Sporadic Tumors Supports a Distinct Entity","volume":"44","author":"RB Shah","year":"2020","journal-title":"The American journal of surgical pathology"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"4043","DOI":"10.3390\/cancers15164043","article-title":"Recent Advances in Renal Tumors with TSC\/mTOR Pathway Abnormalities in Patients with Tuberous Sclerosis Complex and in the Sporadic Setting","volume":"15","author":"P Kapur","year":"2023","journal-title":"Cancers"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1007\/s00428-022-03283-x","article-title":"Low-grade oncocytic tumor of kidney harboring TSC\/MTOR mutation: clinicopathologic, immunohistochemical and molecular characteristics support a distinct entity","volume":"480","author":"H-Z Zhang","year":"2022","journal-title":"Virchows Archiv"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1038\/s41379-021-00923-6","article-title":"Eosinophilic vacuolated tumor (EVT) of kidney demonstrates sporadic TSC\/MTOR mutations: next-generation sequencing multi-institutional study of 19 cases","volume":"35","author":"M Farca\u015f","year":"2022","journal-title":"Modern pathology"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1097\/PAS.0000000000000508","article-title":"Eosinophilic, Solid, and Cystic Renal Cell Carcinoma: Clinicopathologic Study of 16 Unique, Sporadic Neoplasms Occurring in Women","volume":"40","author":"K Trpkov","year":"2016","journal-title":"The American journal of surgical pathology"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1097\/PAS.0000000000001111","article-title":"Eosinophilic Solid and Cystic (ESC) Renal Cell Carcinomas Harbor TSC Mutations: Molecular Analysis Supports an Expanding Clinicopathologic Spectrum","volume":"42","author":"DN Palsgrove","year":"2018","journal-title":"The American journal of surgical pathology"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.humpath.2018.05.023","article-title":"Eosinophilic solid and cystic renal cell carcinoma mimicking epithelioid angiomyolipoma: series of 4 primary tumors and 2 metastases","volume":"80","author":"MS Tretiakova","year":"2018","journal-title":"Hum Pathol"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1007\/s00428-023-03688-2","article-title":"mTOR eosinophilic renal cell carcinoma: a distinctive tumor characterized by mTOR mutation, loss of chromosome 1, cathepsin-K expression, and response to target therapy","volume":"483","author":"A Cali\u00f2","year":"2023","journal-title":"Virchows Archiv"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1002\/path.2932","article-title":"Aberrant succination of proteins in fumarate hydratase-deficient mice and HLRCC patients is a robust biomarker of mutation status","volume":"225","author":"C Bardella","year":"2011","journal-title":"The Journal of pathology"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"3387","DOI":"10.1073\/pnas.051633798","article-title":"Inherited susceptibility to uterine leiomyomas and renal cell cancer","volume":"98","author":"V Launonen","year":"2001","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1007\/s00292-021-00977-y","article-title":"Das FH-defiziente Nierenzellkarzinom erweitert das Spektrum der papill\u00e4ren Tumoren in der Niere","volume":"42","author":"N Rupp","year":"2021","journal-title":"Der Pathologe"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"2346","DOI":"10.1056\/NEJMoa2200900","article-title":"Bevacizumab and Erlotinib in Hereditary and Sporadic Papillary Kidney Cancer","volume":"392","author":"R Srinivasan","year":"2025","journal-title":"The New England journal of medicine"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"4398","DOI":"10.1038\/s41467-025-59513-8","article-title":"Comprehensive molecular profiling of FH-deficient renal cell carcinoma identifies molecular subtypes and potential therapeutic targets","volume":"16","author":"X Zhang","year":"2025","journal-title":"Nature communications"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.1097\/PAS.0000000000000720","article-title":"TFEB-amplified Renal Cell Carcinomas: An Aggressive Molecular Subset Demonstrating Variable Melanocytic Marker Expression and Morphologic Heterogeneity","volume":"40","author":"P Argani","year":"2016","journal-title":"The American journal of surgical pathology"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1097\/PAS.0000000000000631","article-title":"TFE3-Fusion Variant Analysis Defines Specific Clinicopathologic Associations Among Xp11 Translocation Cancers","volume":"40","author":"P Argani","year":"2016","journal-title":"The American journal of surgical pathology"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1097\/PAS.0000000000001307","article-title":"TFEB Expression Profiling in Renal Cell Carcinomas: Clinicopathologic Correlations","volume":"43","author":"S Gupta","year":"2019","journal-title":"The American journal of surgical pathology"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1093\/oncolo\/oyac262","article-title":"Immune Checkpoint Therapy Combinations in Adult Advanced MiT Family Translocation Renal Cell Carcinomas","volume":"28","author":"O Alhalabi","year":"2023","journal-title":"The oncologist"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2021.110190","article-title":"Integrative clinical and molecular characterization of translocation renal cell carcinoma","volume":"38","author":"Z Bakouny","year":"2022","journal-title":"Cell reports"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.1038\/s41379-021-00779-w","article-title":"New developments in existing WHO entities and evolving molecular concepts: The Genitourinary Pathology Society (GUPS) update on renal neoplasia","volume":"34","author":"K Trpkov","year":"2021","journal-title":"Modern pathology"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.eururo.2018.03.032","article-title":"Responses to Alectinib in ALK-rearranged Papillary Renal Cell Carcinoma","volume":"74","author":"SK Pal","year":"2018","journal-title":"European urology"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1016\/j.eururo.2022.06.016","article-title":"The 2022 World Health Organization Classification of Tumours of the Urinary System and Male Genital Organs-Part A: Renal, Penile, and Testicular Tumours","volume":"82","author":"H Moch","year":"2022","journal-title":"European urology"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"2564","DOI":"10.1038\/s41379-020-0578-0","article-title":"ALK rearranged renal cell carcinoma (ALK-RCC): a multi-institutional study of twelve cases with identification of novel partner genes CLIP1, KIF5B and KIAA1217","volume":"33","author":"N Kuroda","year":"2020","journal-title":"Modern pathology"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfaf253","article-title":"10 tips on how to take a proper family history in CKD patient care","volume":"18","author":"E Cornec-Le Gall","year":"2025","journal-title":"Clinical Kidney Journal"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfaf092","article-title":"Chronic Kidney Disease of unexplained cause (CKDx): a consensus statement by the Genes & Kidney Working Group of the ERA. Nephrology, dialysis, transplantation","volume":"40","author":"J Halbritter","year":"2025","journal-title":"Nephrol Dial Transplant"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/S1470-2045(25)00099-3","article-title":"Belzutifan for von Hippel-Lindau disease-associated renal cell carcinoma and other neoplasms (LITESPARK-004): 50 months follow-up from a single-arm, phase 2 study","volume":"26","author":"R Srinivasan","year":"2025","journal-title":"The Lancet. Oncology"}],"container-title":["Aktuelle Urologie"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2714-2212.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T23:40:54Z","timestamp":1771285254000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2714-2212"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,4]]},"references-count":50,"journal-issue":{"issue":"01","published-online":{"date-parts":[[2026,2,16]]},"published-print":{"date-parts":[[2026,2]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2714-2212","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0001-7868","1438-8820"],"issn-type":[{"value":"0001-7868","type":"print"},{"value":"1438-8820","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,4]]}}}